Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Bullboard Posts
Post by bilosellhion Sep 29, 2003 5:29pm
362 Views
Post# 6471736

PP Question

PP Questionif this pp was a potential partner making a "down payment", or was represented by other institutions "approaching" BT & onc to get in "for the ride", why did cannacord get a 20% commission on the deal??? the whole deal reaks to me - the timing of it (before release of ph I/II trial results), the lack of clarity/accountability of what the money is needed for (sorry general corporate purposes and trials doesn't cut it when BT made a point of saying prior to the last two financings that onc had enough to complete ph II), and the 20% commission to a brokerage which hasn't done much if anything to support this stock, and with some indication that they have shorted it to the detriment of the same small shareholders who have supported onc from the beginning. you can read whatever positive spin you want into this pp, but ignoring these basic concerns and simply dismiss them, doesn't cut it imo.
Bullboard Posts